Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NovoFine needle 6 mm, NovoFine needle 4 mm · 3 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| NovoFine® needle 6 mm | DEVICE | - |
| NovoFine® needle 8 mm | DEVICE | - |
| NovoFine® needle 12 mm | DEVICE | - |
| NovoFine® needle 4 mm | DEVICE | - |
Inclusion Criteria: * Children/adolescents with type 1 diabetes mellitus * Usage of NovoPen® 1.5 for at least 3 months * Duration of insulin treatment more than 1 year * Normal weight according to Tanner scales * The means of the last 2 HbA1c measurements taken within the last 6 months must be less...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NovoFine needle 6 mm and NovoFine needle 4 mm are insulin pen needles used for insulin delivery in people with diabetes, including type 1 and type 2 diabetes. They are designed to attach to insulin pens and are available in different lengths to accommodate various body types and injection sites.
NovoFine needle 6 mm and NovoFine needle 4 mm are developed by Novo Nordisk A/S, a Danish pharmaceutical company listed on the New York Stock Exchange under the ticker NVO. Novo Nordisk specializes in diabetes care and produces a range of insulin delivery devices.
NovoFine needle 6 mm and NovoFine needle 4 mm are in Phase 3 clinical development. They are investigational devices being studied for use in diabetes management. They are not yet approved by regulatory authorities and remain in clinical trials.
NovoFine needle 6 mm and NovoFine needle 4 mm have been studied in three completed clinical trials: NCT00343343 compared 4 mm and 6 mm needles in 62 participants in Denmark; NCT00871416 examined insulin deposits with 6 mm and 12 mm needles in 48 participants; and NCT00872560 compared two NovoFine needles on insulin reflux in 60 participants in Italy.
NovoFine needle 6 mm and NovoFine needle 4 mm are both insulin pen needles from the same product line, but they differ in length. The 6 mm needle is longer than the 4 mm needle. They are designed for subcutaneous insulin injection and are compared in clinical trials to assess their performance.